β-Actin: An Emerging Biomarker in Ischemic Stroke.

Area of Science:

• Neurology
• Biomarker Discovery
• Cerebrovascular Diseases

Background:

• Current ischemic stroke diagnosis relies heavily on neuroimaging, which has significant limitations.
• Beta-actin (β-actin) is recognized as a biomarker in various cancers.
• Understanding of β-actin's role in neurology, particularly in ischemic stroke, is limited.

Purpose of the Study:

• To comprehensively review the literature on β-actin in ischemic stroke.
• To evaluate the potential of serum β-actin as an early diagnostic blood biomarker for ischemic stroke.
• To explore the underlying mechanisms and future therapeutic strategies related to β-actin in stroke.

Main Methods:

• Systematic review of human and preclinical studies.
• Analysis of existing literature on β-actin's role in cerebral ischemia.
• Focus on recent findings regarding serum β-actin levels in acute ischemic stroke.

Main Results:

• Preclinical studies primarily investigate β-actin's role during cerebral ischemia.
• Emerging human studies report significant increases in serum β-actin during early acute cerebral ischemia.
• Serum β-actin presents a potential early diagnostic marker.

Conclusions:

• Serum β-actin is a promising candidate for early ischemic stroke detection.
• Further research is needed to elucidate β-actin's precise role and mechanisms in stroke.
• Investigating β-actin may lead to novel diagnostic and therapeutic approaches for stroke.